Skip to main content
Erschienen in: hautnah 3/2017

20.04.2017 | Leitthema

Hautmanifestationen beim metabolischen Syndrom

verfasst von: Dr. G. Holzer, B. Straßegger, B. Volc-Platzer

Erschienen in: hautnah | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Der Begriff metabolisches Syndrom (MetS) beschreibt die Häufung mehrerer Risikofaktoren, die das Risiko für Herz-Kreislauf-Erkrankungen und Diabetes mellitus Typ II deutlich erhöhen. Arterielle Hypertonie, Hyperglykämie, Dyslipidämie und viszerale Fettleibigkeit sind die Hauptrisikofaktoren. Das MetS ist keine dermatologische Diagnose per se, dennoch können einige Hautmanifestationen Hinweise für ein beginnendes MetS liefern und dadurch eine frühzeitige Diagnose und Therapie ermöglichen, um die Folgeschäden des MetS zu verhindern.

Kutane Manifestationen

Acanthosis nigricans und multiple weiche Fibrome können Zeichen einer Insulinresistenz und pathologischen Glukosetoleranz, Xanthome und Xanthelasmen Zeichen einer Dyslipidämie sein. Patienten mit Typ-II-Diabetes zeigen zahlreiche mehr oder weniger spezifischen Hautveränderungen. Psoriasis und Hidradenitis suppurativa sind häufig mit dem MetS und Adipositas vergesellschaftet. Akne und Hirsutismus sind häufige kutane Androgenisierungserscheinungen im Rahmen eines polyzystischen Ovarsyndroms (PCOS), bei dem Hyperinsulinämie eine zentrale pathogenetische Rolle spielt. Das MetS ist ein integraler Bestandteil des PCOS.

Schlussfolgerung

Die zunehmende Kenntnis enger Zusammenhänge zwischen MetS und häufigen Hauterkrankungen erfordert, diese Perspektive in das therapeutische Management einzubinden. Dem Dermatologen kommt hierbei eine Schlüsselrolle in der frühen Erkennung von Zeichen des MetS zu.
Literatur
1.
Zurück zum Zitat Al-Himdani S, Ud-Din S, Gilmore S et al (2014) Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. Br J Dermatol 170:527–547CrossRefPubMed Al-Himdani S, Ud-Din S, Gilmore S et al (2014) Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. Br J Dermatol 170:527–547CrossRefPubMed
2.
Zurück zum Zitat Alberti G, Zimmet P, Shaw J et al (2006) The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, Brussels Alberti G, Zimmet P, Shaw J et al (2006) The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, Brussels
3.
Zurück zum Zitat Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed
4.
Zurück zum Zitat Alikhan A, Lynch PJ, Eisen DB (2009) Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539–561 (quiz 562–533)CrossRefPubMed Alikhan A, Lynch PJ, Eisen DB (2009) Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539–561 (quiz 562–533)CrossRefPubMed
5.
Zurück zum Zitat Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 68:654–662CrossRefPubMed Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 68:654–662CrossRefPubMed
6.
Zurück zum Zitat Azziz R, Carmina E, Dewailly D et al (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237–4245CrossRefPubMed Azziz R, Carmina E, Dewailly D et al (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237–4245CrossRefPubMed
7.
Zurück zum Zitat Azziz R, Woods KS, Reyna R et al (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749CrossRefPubMed Azziz R, Woods KS, Reyna R et al (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749CrossRefPubMed
8.
Zurück zum Zitat Balta I, Ekiz O, Ozuguz P et al (2015) Insulin resistance in patients with post-adolescent acne. Int J Dermatol 54:662–666CrossRefPubMed Balta I, Ekiz O, Ozuguz P et al (2015) Insulin resistance in patients with post-adolescent acne. Int J Dermatol 54:662–666CrossRefPubMed
9.
Zurück zum Zitat Behm B, Schreml S, Landthaler M et al (2012) Skin signs in diabetes mellitus. J Eur Acad Dermatol Venereol 26:1203–1211CrossRefPubMed Behm B, Schreml S, Landthaler M et al (2012) Skin signs in diabetes mellitus. J Eur Acad Dermatol Venereol 26:1203–1211CrossRefPubMed
10.
Zurück zum Zitat Bergman R, Kasif Y, Aviram M et al (1996) Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76:107–110PubMed Bergman R, Kasif Y, Aviram M et al (1996) Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76:107–110PubMed
11.
Zurück zum Zitat Brickman WJ, Huang J, Silverman BL et al (2010) Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 156:87–92CrossRefPubMed Brickman WJ, Huang J, Silverman BL et al (2010) Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 156:87–92CrossRefPubMed
12.
Zurück zum Zitat Buzney E, Sheu J, Buzney C et al (2014) Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. J Am Acad Dermatol 71:859 e851–859 e815 (quiz 873–854)CrossRef Buzney E, Sheu J, Buzney C et al (2014) Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. J Am Acad Dermatol 71:859 e851–859 e815 (quiz 873–854)CrossRef
13.
Zurück zum Zitat Canoui-Poitrine F, Revuz JE, Wolkenstein P et al (2009) Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 61:51–57CrossRefPubMed Canoui-Poitrine F, Revuz JE, Wolkenstein P et al (2009) Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 61:51–57CrossRefPubMed
15.
Zurück zum Zitat Dassanayake AS, Kasturiratne A, Niriella MA et al (2011) Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes 4:25CrossRefPubMedPubMedCentral Dassanayake AS, Kasturiratne A, Niriella MA et al (2011) Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes 4:25CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Davidovici BB, Sattar N, Prinz J et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785–1796CrossRefPubMed Davidovici BB, Sattar N, Prinz J et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785–1796CrossRefPubMed
17.
Zurück zum Zitat Dokras A, Bochner M, Hollinrake E et al (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106:131–137CrossRefPubMed Dokras A, Bochner M, Hollinrake E et al (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106:131–137CrossRefPubMed
18.
Zurück zum Zitat Gold DA, Reeder VJ, Mahan MG et al (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 70:699–703CrossRefPubMed Gold DA, Reeder VJ, Mahan MG et al (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 70:699–703CrossRefPubMed
19.
Zurück zum Zitat Guarneri C, Guarneri F, Borgia F et al (2005) Finger pebbles in a diabetic patient: Huntley’s papules. Int J Dermatol 44:755–756CrossRefPubMed Guarneri C, Guarneri F, Borgia F et al (2005) Finger pebbles in a diabetic patient: Huntley’s papules. Int J Dermatol 44:755–756CrossRefPubMed
20.
Zurück zum Zitat Housman E, Reynolds RV (2014) Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol 71:847 e841 (quiz 857–848)CrossRef Housman E, Reynolds RV (2014) Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol 71:847 e841 (quiz 857–848)CrossRef
21.
Zurück zum Zitat Kaymak Y, Adisen E, Ilter N et al (2007) Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne. J Am Acad Dermatol 57:819–823CrossRefPubMed Kaymak Y, Adisen E, Ilter N et al (2007) Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne. J Am Acad Dermatol 57:819–823CrossRefPubMed
22.
Zurück zum Zitat Kromann CB, Ibler KS, Kristiansen VB et al (2014) The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 94:553–557CrossRefPubMed Kromann CB, Ibler KS, Kristiansen VB et al (2014) The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 94:553–557CrossRefPubMed
23.
Zurück zum Zitat Legro RS, Myers ER, Barnhart HX et al (2006) The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril 86:914–933CrossRefPubMed Legro RS, Myers ER, Barnhart HX et al (2006) The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril 86:914–933CrossRefPubMed
24.
Zurück zum Zitat Litonjua P, Pinero-Pilona A, Aviles-Santa L et al (2004) Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract 10:101–106CrossRefPubMed Litonjua P, Pinero-Pilona A, Aviles-Santa L et al (2004) Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract 10:101–106CrossRefPubMed
25.
Zurück zum Zitat Miller IM, Ellervik C, Vinding GR et al (2014) Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 150:1273–1280CrossRefPubMed Miller IM, Ellervik C, Vinding GR et al (2014) Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 150:1273–1280CrossRefPubMed
26.
Zurück zum Zitat Muller SA, Winkelmann RK (1966) Necrobiosis lipoidica diabeticorum histopathologic study of 98 cases. Arch Dermatol 94:1–10CrossRefPubMed Muller SA, Winkelmann RK (1966) Necrobiosis lipoidica diabeticorum histopathologic study of 98 cases. Arch Dermatol 94:1–10CrossRefPubMed
28.
Zurück zum Zitat O’toole EA, Kennedy U, Nolan JJ et al (1999) Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 140:283–286CrossRefPubMed O’toole EA, Kennedy U, Nolan JJ et al (1999) Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 140:283–286CrossRefPubMed
29.
Zurück zum Zitat Perez MI, Kohn SR (1994) Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 30:519–531 (quiz 532–514)CrossRefPubMed Perez MI, Kohn SR (1994) Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 30:519–531 (quiz 532–514)CrossRefPubMed
30.
31.
Zurück zum Zitat Rasi A, Soltani-Arabshahi R, Shahbazi N (2007) Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case-control study. Int J Dermatol 46:1155–1159CrossRefPubMed Rasi A, Soltani-Arabshahi R, Shahbazi N (2007) Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case-control study. Int J Dermatol 46:1155–1159CrossRefPubMed
32.
Zurück zum Zitat Reid SD, Ladizinski B, Lee K et al (2013) Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 69:783–791CrossRefPubMed Reid SD, Ladizinski B, Lee K et al (2013) Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 69:783–791CrossRefPubMed
33.
Zurück zum Zitat Ribera M, Pinto X, Argimon JM et al (1995) Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med 99:485–490CrossRefPubMed Ribera M, Pinto X, Argimon JM et al (1995) Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med 99:485–490CrossRefPubMed
34.
Zurück zum Zitat Romano G, Moretti G, Di Benedetto A et al (1998) Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 39:101–106CrossRefPubMed Romano G, Moretti G, Di Benedetto A et al (1998) Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 39:101–106CrossRefPubMed
35.
Zurück zum Zitat Rosenfield RL (2015) The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. J Pediatr Adolesc Gynecol 28:412–419CrossRefPubMed Rosenfield RL (2015) The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. J Pediatr Adolesc Gynecol 28:412–419CrossRefPubMed
36.
Zurück zum Zitat Rotterdam Ea-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef Rotterdam Ea-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
37.
Zurück zum Zitat Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLOS ONE 7:e31810CrossRefPubMedPubMedCentral Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLOS ONE 7:e31810CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Schilling WH, Crook MA (2014) Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk. Int J Dermatol 53:1062–1069CrossRefPubMed Schilling WH, Crook MA (2014) Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk. Int J Dermatol 53:1062–1069CrossRefPubMed
39.
Zurück zum Zitat Segal P, Insull W Jr., Chambless LE et al (1986) The association of dyslipoproteinemia with corneal arcus and xanthelasma. The Lipid Research Clinics Program Prevalence Study. Circulation 73:I108–118CrossRefPubMed Segal P, Insull W Jr., Chambless LE et al (1986) The association of dyslipoproteinemia with corneal arcus and xanthelasma. The Lipid Research Clinics Program Prevalence Study. Circulation 73:I108–118CrossRefPubMed
40.
Zurück zum Zitat Shemer A, Bergman R, Linn S et al (1998) Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol 37:113–115CrossRefPubMed Shemer A, Bergman R, Linn S et al (1998) Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol 37:113–115CrossRefPubMed
41.
42.
43.
Zurück zum Zitat Timpatanapong P, Rojanasakul A (1997) Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 24:223–229CrossRefPubMed Timpatanapong P, Rojanasakul A (1997) Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 24:223–229CrossRefPubMed
44.
Zurück zum Zitat Verdolini R, Clayton N, Smith A et al (2013) Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 27:1101–1108CrossRefPubMed Verdolini R, Clayton N, Smith A et al (2013) Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 27:1101–1108CrossRefPubMed
45.
Zurück zum Zitat Wolff K, Johnson RA, Saavedra AP (2013) Color Atlas and Synopsis of Clinical Dermatology. Mc Graw Hill Education, New York Wolff K, Johnson RA, Saavedra AP (2013) Color Atlas and Synopsis of Clinical Dermatology. Mc Graw Hill Education, New York
46.
Zurück zum Zitat Yildiz BO, Knochenhauer ES, Azziz R (2008) Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93:162–168CrossRefPubMed Yildiz BO, Knochenhauer ES, Azziz R (2008) Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93:162–168CrossRefPubMed
Metadaten
Titel
Hautmanifestationen beim metabolischen Syndrom
verfasst von
Dr. G. Holzer
B. Straßegger
B. Volc-Platzer
Publikationsdatum
20.04.2017
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 3/2017
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-017-0231-y

Weitere Artikel der Ausgabe 3/2017

hautnah 3/2017 Zur Ausgabe